Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates

Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer harboring MET exon 14 skipping alterations. The aims of this work were to investigate the potential for drug-drug interactions via cytochrome P4...

Descripción completa

Detalles Bibliográficos
Autores principales: Yalkinoglu, Özkan, Becker, Andreas, Krebs-Brown, Axel, Vetter, Claudia, Lüpfert, Christian, Perrin, Dominique, Heuer, Jürgen, Biedert, Herlind, Hirt, Stefan, Bytyqi, Afrim, Bachmann, Angelika, Strotmann, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447267/
https://www.ncbi.nlm.nih.gov/pubmed/37415001
http://dx.doi.org/10.1007/s10637-023-01378-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447267/
https://www.ncbi.nlm.nih.gov/pubmed/37415001
http://dx.doi.org/10.1007/s10637-023-01378-z

Ejemplares similares